Literature DB >> 12219660

[Extracorporeal shockwave therapy (ESWT) in epicondylitis humeri radialis. Short-term and intermediate-term results].

T Decker1, B Kuhne, F Göbel.   

Abstract

Eighty-five patients with a chronic therapy-resistant lateral epicondylitis (LE) were treated with extracorporeal shock wave therapy (ESWT). All patients had been previously treated with physical therapy, local injections, and other conservative procedures for at least 6 months. Three weekly sessions of ESWT were performed under local anesthesia with a Dornier Epos Ultra (energy flux density 0.05-0.18 mJ/mm2). Complications such as small hematomas were only found in four patients. After a mean follow-up of 30.7 months, 78 patients could be evaluated with the Roles and Maudsley score. Of these 30.8% had an excellent and 42.3% a good result, while 11.5% had a fair and 15.4% a distinctly poor outcome. Pain perception under stress conditions was assessed by the visual analog scale, which decreased significantly from 6.5 before ESWT to 2.0 after ESWT (p < 0.0001). A graduated local pressure pain on lateral epicondyle remained in 71.8% of the patients as a residual symptom. Sixty-two patients declared their satisfaction with the ESWT and would agree to have the therapy repeated.

Entities:  

Mesh:

Year:  2002        PMID: 12219660     DOI: 10.1007/s00132-002-0322-0

Source DB:  PubMed          Journal:  Orthopade        ISSN: 0085-4530            Impact factor:   1.087


  2 in total

1.  Efficacy of tennis elbow (epicondylitis humeri radialis) treatment in CBR "Praxis".

Authors:  Dzemal Pecar; Dijana Avdić
Journal:  Bosn J Basic Med Sci       Date:  2009-02       Impact factor: 3.363

2.  Extracorporeal Shockwave Therapy Modulates the Expressions of Proinflammatory Cytokines IL33 and IL17A, and Their Receptors ST2 and IL17RA, within the Articular Cartilage in Early Avascular Necrosis of the Femoral Head in a Rat Model.

Authors:  Jai-Hong Cheng; Shun-Wun Jhan; Chieh-Cheng Hsu; Hung-Wen Chiu; Shan-Ling Hsu
Journal:  Mediators Inflamm       Date:  2021-07-09       Impact factor: 4.711

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.